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Abstract
Background: We have previously reported the role of anti-angiogenic factors in inducing the transition from compensatory
cardiac hypertrophy to heart failure and the significance of MMP-9 and TIMP-3 in promoting this process during pressure
overload hemodynamic stress. Several studies reported the evidence of cardiac autophagy, involving removal of cellular
organelles like mitochondria (mitophagy), peroxisomes etc., in the pathogenesis of heart failure. However, little is known
regarding the therapeutic role of mitochondrial division inhibitor (Mdivi) in the pressure overload induced heart failure. We
hypothesize that treatment with mitochondrial division inhibitor (Mdivi) inhibits abnormal mitophagy in a pressure overload
heart and thus ameliorates heart failure condition.
Materials and Methods: To verify this, ascending aortic banding was done in wild type mice to create pressure overload
induced heart failure and then treated with Mdivi and compared with vehicle treated controls.
Results: Expression of MMP-2, vascular endothelial growth factor, CD31, was increased, while expression of anti angiogenic
factors like endostatin and angiostatin along with MMP-9, TIMP-3 was reduced in Mdivi treated AB 8 weeks mice compared
to vehicle treated controls. Expression of mitophagy markers like LC3 and p62 was decreased in Mdivi treated mice
compared to controls. Cardiac functional status assessed by echocardiography showed improvement and there is also a
decrease in the deposition of fibrosis in Mdivi treated mice compared to controls.
Conclusion: Above results suggest that Mdivi inhibits the abnormal cardiac mitophagy response during sustained pressure
overload stress and propose the novel therapeutic role of Mdivi in ameliorating heart failure.
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Introduction
Heart failure is a multi factorial syndrome and is the leading
cause of mortality worldwide [1]. Pressure overload created
hemodynamic stress results in initial compensated cardiac
hypertrophy and later leads to decompensated heart failure on
sustained overload. Vast research has been going on to study the
pathogenesis of heart failure including matrix metalloproteinases
(MMPs), their tissue inhibitors (TIMPs) induced cardiac remod-
eling and role of anti angiogenic factors [2]. More recently several
studies reported the evidence of cardiac autophagy in the
pathogenesis of load induced heart failure [3,4,5,6]. Autophagy
is a lysosomal mediated process scavenging the old nonfunctional
and damaged cellular structures like mitochondria, peroxisomes
and maintains the homeostasis of cellular environment [7,8,9].
Though basal level autophagy is required, stress induced abnormal
autophagy can be detrimental. A selective form of autophagy
through which damaged mitochondria are removed by lysosomal
degradation is termed as mitophagy [10,11].
The dynamic process of myocyte contraction and relaxation is
continuous energy demand process. Cardiac myocytes are highly
packed with mitochondria and heart relies mostly on mitochon-
drial metabolism for its energy needs [12,13]. Mitochondrial
structural abnormalities along with the decreased levels of high
energy phosphates are reported in cardiac myocytes of advanced
heart failure stage [12,14,15]. Mitochondria are the main source
of reactive oxygen species (ROS) that are involved in the
pathogenesis of heart failure [16]. ROS, produced by mitochon-
dria during stress can be detrimental to their own lipids, proteins
and DNA and lead to mitochondrial dysfunction [17]. Increased
ROS lead to loss of mitochondrial membrane potential (DYm),
which later signals for mitochondrial fragmentation (fission) and
mitophagy [10,11,18].
Mitochondrial dynamics involve fission and fusion mechanisms
regulated by enzymes that hydrolyze guanidine triphosphates
(GTPases) [19]. Dynamin related protein (Drp1) and fission
protein (hfis1) are mainly involved in mitochondrial fission
mechanism [20,21], whereas mitofusins 1 and 2 help in fusion
mechanism [22,23]. Activation of Drp1 is reported to stimulate the
fission process during mitophagy [24,25]. Mdivi-1 (Mitochondrial
division inhibitor-1), a newly found potential inhibitor of Drp1 was
reported to block the mitochondrial fission and confers cardio
protection in experimental cardiac ischemia reperfusion studies in
mice [26].
PLoS ONE | www.plosone.org 1 March 2012 | Volume 7 | Issue 3 | e32388In the current study, we have created ascending aortic banding
in mice to create pressure overload stress on the heart and later
treated with potential mitochondrial division inhibitor (Drp-1
inhibitor), Mdivi-1 to study its effects on ventricular remodeling in
heart failure. To our knowledge, we are the first to report the
therapeutic role of Mdivi-1 during pressure overload in amelio-
rating the heart failure.
Materials and Methods
Animals
Wild type mice (WT, C57BL6/J) aged 8 weeks were procured
from Jackson Laboratories (Bar Harbor, Me.; USA) and housed in
the animal care facility at University of Louisville with access to
standard chow and water. Ascending aortic banding was created
in mice of 12 weeks age with an approximate weight of 23–25
grams. Each group is further divided into sham, AB 8 weeks
treated with vehicle control and Mdivi. After the study period
animals were euthanized in accordance with National Institute of
Health Guidelines for animal research and were reviewed and
approved by the Institute Animal Care and use Committee of
University of Louisville (IACUC # 07134).
Pressure overload animal model
Ascending aortic banding was done as described previously
[2,27].Briefly, under sodium pentobarbital anesthesia, animals
were intubated and ventilated with Harvard mini ventilator. Body
temperature was maintained with a heating pad. Under sterile
surgical environment thorax was opened by left parasternal
thoracotomy and ascending aorta was dissected and separated
from the adjacent structures. Ascending aorta was ligated with 6–0
silk by placing the 26 g needle on the aorta for optimum
constriction. Needle was quickly removed to keep the constricted
aorta patent. Wound was closed in layers using 6–0 vicryl for the
subcutaneous tissues and 5–0 silk to the skin. The mortality rate
was less than 20% with the surgery. All animals were given post-
operative analgesia with intraperitoneal injection of Ketofen,
5 mg/Kg body weight. Sham group of animals underwent similar
procedure except the aortic constriction. By creating pressure
overload using ascending aortic banding model, heart failure
develops by 8 weeks. Our previous experiments showed the
pathophysiological and histological changes associated with heart
failure are achieved by 8 weeks [2,27]. Researchers showed the
therapeutic effects of Mdivi in ischemia reperfusion studies
suggesting that it prevents heart failure [26]. Here we show that
Mdivi can alleviate left ventricular dysfunction during heart failure
condition.
Mdivi treatment
Mitochondrial division inhibitor, Mdivi-1 was purchased from
Enzo life sciences (Plymouth meeting, PA). Mdivi-1 was given as
intraperitoneal injection in the dose of 50 mg per kg body weight
for 7 days. Since Mdivi was dissolved in di-methyl sulfoxide
(DMSO), we gave similar dilution of DMSO in the normal saline
as vehicle control. At the end of the treatment, animals were
euthanized and organs were harvested and stored at 280uc.
Antibodies & Reagents
The following primary antibodies were used for immunohisto-
chemical data: rabbit polyclonal anti-angiostatin, mouse mono-
clonal anti-endostatin, rabbit polyclonal MMP-2, rabbit polyclonal
MMP-9, rabbit polyclonal antibody against TIMP-3, LC3, mouse
monoclonal mitochondrial marker- MTCO-2 and mouse mono-
clonal P62 antibodies. These antibodies were purchased from
Abcam (Cambridge, MA). Anti-mouse VEGF antibody was
purchased from R&D systems (Minneapolis, MN). Anti-mouse
CD 31 or PECAM (Platelet endothelial cell adhesion molecule)
was purchased from BD Pharmingen (Sandiego, CA). Cleaved
caspace-3 antibody (Cell Signaling #9661) from rabbit source was
used. Following fluorescent secondary antibodies for Immunohis-
tochemistry (IHC) were ordered from Invitrogen (Carlsbad, CA):
Texas Red raised in mouse, Alexa Fluor 488 ,594 raised in rabbit
and Alexa fluor 647 raised in rat.
Echocardiography
Left ventricular functional status was assessed by transthoracic
echocardiography as described elsewhere [27]. Briefly, echo was
performed on mice to achieve two dimensional left ventricle
images from an apical view using a SONOS 5500 or 2500;
Hewlett-Packard, Inc. and a 12.5 MHz transducer. Tribromo
ethanol (TBE) anesthesia (intra peritoneal dose of 240 mg/kg body
weight), was used to minimize the cardio depressing actions
produced by other anesthetics [28]. Mice were depilated with hair
removal cream (Nair) and placed on a heating pad to maintain
body temperature. The functional status of the heart was assessed
by LVIDd, LVIDs, LVPWD and %FS. %FS is the most common
method to evaluate left ventricular function in murine echocar-
diography [29].
Cryosectioning
After euthanizing the mice, heart tissue was harvested and
washed thoroughly in phosphate buffered saline (PBS) and
preserved in a Peel-A-Way disposable plastic tissue embedding
moulds (Polysciences inc., Warrington, PA.,USA) having tissue
freezing media (Triangle Biomedical Sciences, Durham, N.C.,
USA) at 70u C until further use. 5 mm thickness tissue sections
were made using Cryocut (Leica CM 1850) and placed on
Super frost plus microscope slides, air-dried and processed for
staining.
Immunohistochemistry
5 mm thick frozen sections of the heart were used to perform
immunohistochemistry (IHC) following standard IHC protocol
(Abcam) as described previously [2]. Following overnight primary
antibody application, secondary antibodies were applied as
described in the protocol and stained slides were mounted and
visualized with fluorescence by a laser scanning confocal micro-
scope (Olympus FluoView1000) with an appropriate filter.
Tunel assay
Tunel staining was conducted on frozen heart sections using a
commercially available kit (Dead End Fluorometric TUNEL
System; Promega). Staining was done according to manufacturer’s
instructions keeping positive and negative controls.
Masson’s Trichrome Staining
Fibrosis or collagen deposition in tissue sections was assessed by
Mason’s trichrome (Richard-Allan Scientific, Kalamazoo, MI,
USA) staining as per the manufacturer’s instructions. Collagen
appeared as blue color.
Image Proplus software
Images from Immunohistochemistry and Masson’s trichrome
staining were analyzed with Image Proplus software. Image
analysis was done using image-pro software in confocal images
taking different optical fields at random into consideration while
the densitometry analysis was done using Bio-Rad software.
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Total RNA from mouse heart was isolated using Trizol reagent
(Gibco BRL) following manufacturer’s instructions. RNA quality was
assessed by Nano Drop ND-1000 and only highly pure quality RNA
(260/280–2.00 and 260/230–2.0) was used for RT-PCR studies.
RT-PCR
cDNA waspreparedusing promega kit.Thereverse transcription
program was 25uC for 10 min, 42uC for 50 min, and then 70uC for
15 min. RT-PCR was performed for mRNA expression of MMP-
2,-9,TIMP-3, VEGF, angiostatin, endostatin in study groups using
ImProm-II
TM Reverse Transcription system kit (Promega Corpo-
ration, Madison, WI, USA, cat # A3800). For gene amplification
the RT-PCR program was 95uC–7.00 min, [95uC–0.50 min,
55uC–1.00 min, 72uC–1.00 min]634, 72uC–5.00 min, 4uC-‘.
For VEGF, the RT-PCR program was 95u C-7.00 min, [95uC–
0.50 min, 63uC–1.00 min,95uC- 0.50 min,63uC-1.00 min, 72uC–
1.00 min]634, 72uC–5.00 min, 4uC-‘. The primers for RT-PCR
are obtained from Invitrogen (carlsbad,CA) and described in
Table 1. The RT-PCR product was electrophoresed on 1% agarose
gel in TAE with 0.008% ethidium bromide.
Quantitative real time PCR
cDNA obtained as mentioned above method was amplified by
real time PCR method using Sybr green dye. Gene amplification
program used was ‘‘95uC-10.00 min, 95uC-0.30 min, 58uC-
1.00 min640, 72uC-0.30 min, 95uC- 1.00 min, 55uC-0.30 min,
95uC-0.30 min.
Statistical analysis
All data are expressed as mean 6 SE. One-way analysis
of variance (ANOVA) was performed to test for treatment
effects, and differences between groups were determined using
Tukey’s post-hoc test. A p value ,0.05 was considered to be
significant.
Table 1. mRNA primers.
mRNA Orientation Primer Sequence
Endostatin Forward 5-GTGGGTAACCTTTCTCCTCC-3
Reverse 5-GGTTGACGATGGGCACAGAC-3
Angiostatin Forward 5-GAGGTCAAGGTTGCCATGTT-3
Reverse 5-GTTGCTTGCTTTCCCTCTTG-3
VEGF Forward 5-GGACCCTGGCTTTACTGC-3
Reverse 5-CGGGCTTGGCGATTTAG-3
MMP-2 Forward 5-CACACCAGGTGAAGGATGTG-3
Reverse 5-GCCCTCCTAAGCCAGTCTCT-3
MMP-9 Forward 5-TAGTGAGAGACTCTACACAG-3
Reverse 5-CCACTTCTTGTCAGTGTCGA-3
TIMP-3 Forward 5-GCAGATGAAGATGTACCGAGG-3
Reverse 5-TCAGGGATCTGTGGCGTTGCT-3
GAPDH Forward 5-ATGGGAAGCTGGTCATCAAC-3
Reverse 5-TGTGAGGGAGATGCTCAGTG-3
doi:10.1371/journal.pone.0032388.t001
Figure 1. Mdivi ameliorates left ventricular dysfunction. A) Changes in left ventricular (LV) function following aortic banding (AB) and the
effects of Mdivi treatment, a Drp1 inhibitor. Representative M-mode echocardiography images from sham, sham with Mdivi treatment, AB 8 weeks
with vehicle and Mdivi treatment groups. The bar graphs represent LVIDd (left ventricular internal dimension in diastole), LVPWd (left ventricular
posterior wall dimension in diastole (B), and %FS (percentage fractional shortening) (C). *p,0.05 compared to sham and
#p,0.05 compared to
vehicle treated group. Data represents mean 6SE from n=6 per group.
doi:10.1371/journal.pone.0032388.g001
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PLoS ONE | www.plosone.org 3 March 2012 | Volume 7 | Issue 3 | e32388Figure 2. Mdivi promotes angiogenesis. A) CD-31-immunohistochemical (IHC) staining of heart and secondarily stained with alexaflour 647 in
sham, 8 weeks post-AB (AB 8 wks) treated with vehicle control and Mdivi. The expression of CD31 is seen as red fluorescence intensity (scale bar-
20 mm). C) VEGF-IHC staining of heart sections, secondarily stained with alexaflour 594 in sham, 8 weeks post-AB (AB 8 wks) treated with vehicle
control and Mdivi. The expression of VEGF is seen as red fluorescence intensity (scale bar- 50 mm). B, D) Data represents mean 6SE from n=6 per
group; *p,0.05 compared to sham and
#p,0.05 compared to vehicle treated group.
doi:10.1371/journal.pone.0032388.g002
Figure 3. Mdivi inhibits anti-angiogenic factors. A) IHC staining of heart sections with angiostatin, secondarily stained with alexa fluor 488
fluorescent antibody in sham, 8 weeks post-AB (AB 8 wks) treated with vehicle control and Mdivi. The expression of angiostatin is seen as green
fluorescence intensity (scale bar- 50 mm). C) IHC staining of heart sections with endostatin, secondarily stained with texas red fluorescent antibody in
sham, 8 weeks post-AB (AB 8 wks) treated with vehicle control and Mdivi. The expression of endostatin is seen as red fluorescence intensity (scale
bar- 50 mm). B, D) Data represents mean 6SE from n=6 per group; *p,0.05 was considered significant compared to sham and
#p,0.05 compared
to vehicle treated group.
doi:10.1371/journal.pone.0032388.g003
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PLoS ONE | www.plosone.org 4 March 2012 | Volume 7 | Issue 3 | e32388Figure 4. mRNA expression of endostatin and angiostatin primers. A) RT-PCR: mRNAs are amplified using respective primers and the bands
were quantified using densitometry. B, C) Bar graphs represent respective mRNA expression over GAPDH expression by RT-PCR and real time PCR
assay. Data represents mean 6SE from n=6 per group; *p,0.05 was considered significant compared to sham and
#p,0.05 compared to vehicle
treated group.
doi:10.1371/journal.pone.0032388.g004
Figure 5. Co-localization staining of heart sections with MMP-2 and TIMP-3, secondarily stained with texas red and alexaflour 488
respectively, fluorescent antibodies in sham, in sham, 8 weeks post-AB (AB 8 wks) treated with vehicle control and Mdivi. A) The
expression of MMP-2 is seen as red fluorescence intensity and TIMP-3 as green fluorescence (scale bar- 50 mm). B) Images were analyzed using Image
proplus software and the data represented in bar diagram. Data represents mean 6SE from n=6 per group; *p,0.05 was considered significant
compared to sham and
#p,0.05 compared to vehicle treated group.
doi:10.1371/journal.pone.0032388.g005
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PLoS ONE | www.plosone.org 5 March 2012 | Volume 7 | Issue 3 | e32388Figure 6. mRNA expression of MMP-9 and TIMP-3. A) mRNAs are amplified using respective primers and the bands were quantified using
densitometry. B, C) Bar graphs represent respective mRNA expression over GAPDH expression by RT-PCR and real time PCR assay. Data represents
mean 6SE from n=6 per group; *p,0.05 was considered significant compared to sham and
#p,0.05 compared to vehicle treated group.
doi:10.1371/journal.pone.0032388.g006
Figure 7. IHC staining of heart sections with MMP-9 antibody, secondarily stained with alexaflour 488 fluorescent antibody in
sham, 8 weeks post-AB (AB 8 wks) treated with vehicle control and Mdivi. A) The expression of MMP-9 is seen as green fluorescence
intensity (scale bar- 50 mm). C) Masson’s trichrome blue staining of collagen depicting interstitial fibrosis. Quantification of collagen (blue staining)
was done with the help of Image proplus software and represented in bar diagram. B, D) Data represents mean 6SE from n=6 per group; *p,0.05
was considered significant compared to sham and
#p,0.05 compared to vehicle treated group.
doi:10.1371/journal.pone.0032388.g007
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Left ventricular dysfunction was ameliorated by
treatment with mitochondrial fission inhibitor
cardiac functional status was evaluated by echocardiography to
determine the effect of Mdivi on left ventricular dysfunction.
Echocardiography results showed a decrease in ventricular
chamber diameter and also increase in percentage fractional
shortening (%FS) in Mdivi treated AB 8 weeks group compared to
AB 8 weeks vehicle control group (Figure 1). These findings
suggest that, inhibiting the mitochondrial fragmentation using
Mdivi helps in ameliorating ventricular dysfunction during
pressure overload induced heart failure. To verify any side-effects
of M-divi treatment, sham animals were treated with Mdivi and
left ventricular function by echocardiography was assessed. Based
on previous research studies [26] and from our findings, Mdivi
didn’t exhibit any side effects.
Drp-1 inhibitor, Mdivi promotes angiogenesis
Angiogenesis was assessed by the expression of CD 31 or
PECAM (Platelet endothelial cell adhesion molecule), an angio-
genesis marker and by the expression of vascular endothelial
growth factor (VEGF). Immunohistochemical data showed
increase in the CD31 stained capillaries in Mdivi treated group
compared to corresponding vehicle treated group. Increase in
VEGF expression also confirms this finding and suggests that
minimizing the abnormal mitophagy by Mdivi helps in angiogen-
esis during heart failure condition (Figure 2).
Mdivi reduces the expression of anti-angiogenic factors
and ameliorates ventricular remodeling during heart
failure
To determine the role of Mdivi on anti-angiogenesis, expression
of anti-angiogenic factors like angiostatin and endostatin were
assessed by immunohistochemistry, RT-PCR and real time PCR.
There was increased expression of angiostatin and endostatin in
AB 8 weeks vehicle treated group compared to Mdivi treated
group (Figure 3 & 4). These results suggest that inhibiting the
mitochondrial fission by Mdivi can decrease the expression of anti-
angiogenic factors.
Mdivi regulates extra cellular matrix remodeling by
altering MMP/TIMP expressions during heart failure
To assess the role of Mdivi on MMP/TIMP axis, expression of
MMP-2,-9 and TIMP-3 were determined by immunohistochemis-
try, RT-PCRand realtime PCR.Therewasincreased expression of
MMP-9 and TIMP-3 in AB 8 weeks vehicle treated group
compared to sham. Treatment with Mdivi decreased the expression
of MMP-9 and TIMP-3. In contrast, MMP-2 expression in IHC
data showed increase in Mdivi treated group compared to
corresponding vehicle treated group (Figure 5, 6 & 7). These
Figure 8. Tunnel assay of mouse cardiac sections staining for apoptosis in sham, 8 weeks post-AB (AB 8 wks) treated with vehicle
control and Mdivi. A) Apoptotic cells are seen as green fluorescent dots (scale bar- 10 mm). Positive and negative controls are also represented in
this image. B) Data represents mean 6SE from n=6 per group; *p,0.05 was considered significant compared to sham and
#p,0.05 compared to
vehicle treated group.
doi:10.1371/journal.pone.0032388.g008
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eling by altering the MMP/TIMP axis during pressure overload
induced heart failure. Previously, we and others have shown the
association of MMP-9 and TIMP-3 with collagen deposition and
fibrosis [2,27]. Thus we investigated the role of Mdivi in collagen
deposition or fibrosis through well-established Masson’s trichrome
staining. There was significant increase in collagen deposition in
vehicle treated AB 8 weeks group compared to Mdivi treated and
sham groups (Figure 7). These findings suggest that treatment with
Mdivi reduces fibrosis or collagen deposition.
Mdivi prevents abnormal apoptosis
Apoptosis or cell death during heart failure was assessed by
Tunel assay and activated caspace-3 staining. There was
significant increase in apoptosis level in AB 8 weeks vehicle
treated group. Treatment with Mdivi inhibits the increase in
apoptosis and normalizes to that of sham group (Figure 8 & 9).
These findings suggest the beneficial role in preventing apoptosis.
Treatment with Mdivi minimizes the expression of
autophagy/mitophagy markers and increases the
expression of mitochondrial marker MTCO-2
Autophagy/Mitophagy in heart failure was assessed by
expression of mitophagy markers like LC3 and P62. There was
increase in expression of LC3 and P62 in AB 8 weeks vehicle
treated group compared to sham. Treatment with mitochondrial
fission inhibitor, Mdivi normalized the increased expression of
LC3 and P62 to that of sham group (Figure 10). Expression of
mitochondrial marker MTCO-2 is increased significantly in Mdivi
treated groups compared to untreated groups suggesting the
increased number of mitochondria (Figure 11). These results
suggest that Mdivi inhibits the abnormal mitophagy, restores the
number of mitochondria and helps in ameliorating heart failure
condition.
Discussion
Previous studies reported the induction of autophagy during
pressure overload induced heart failure. Mitochondria being the
main source of cellular reactive oxygen species (ROS), are the
main target for autophagy and thus mitophagy is increased during
end stage of heart failure. Studies also reported that Drp-1
inhibitor, Mdivi inhibits mitochondrial fission during mitophagy
and confers cardio protection during ischemia-reperfusion. The
purpose of this study was to determine the therapeutic role of
Mdivi during pressure overload induced heart failure.
We have previously reported the role of matrix metalloprotei-
nases induced angiogenesis during pressure overload induced
stress in initiating compensated cardiac hypertrophy and the role
of anti angiogenic factors leading to decompensated heart failure
on sustained overload [2,27]. The rationale and hypothesis of this
study were that Mdivi primarily inhibits mitochondrial fission and
thereby inhibits the mitophagy/autophagy during pressure
Figure 9. Activated caspace-3 staining of mouse cardiac sections showing apoptosis in sham, 8 weeks post-AB (AB 8 wks) treated
with vehicle control and Mdivi. A) Apoptotic cells are seen as red fluorescent dots (scale bar- 20 mm). C) Activated caspace-3 +ve cells
represented in an enlarged area. B) Data represents mean 6SE from n=6 per group; *p,0.05 was considered significant compared to sham and
#p,0.05 compared to vehicle treated group.
doi:10.1371/journal.pone.0032388.g009
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abnormal ventricular remodeling by altering MMP/TIMP axis,
inhibits expression of anti angiogenic factors and also promotes
angiogenesis, thus ameliorates heart failure. In our current study,
we found that there is increased induction of cardiac autophagy/
mitophagy and also there is increased apoptosis during heart
failure stage. Finally, treatment with Drp-1 inhibitor, Mdivi-1
confers cardio protection by inhibiting the mitochondrial frag-
mentation that is increased during heart failure.
Heart disease is the number one cause of mortality worldwide.
Recent studies report the role of autophagy or mitophagy in the
pathogenesis of heart failure [3]. Though mitochondrial dynamics
involve both fission and fusion mechanisms, mitochondrial
fragmentation or fission signals the process of mitophagy
[19,30,31,32]. Mdivi is the known potent Drp-1 inhibitor and
has been reported of its protective role in mice models of
experimental ischemia reperfusion studies in both heart and
kidneys [26,33,34]. The significant increase in ventricular
chamber diameter and decrease in fractional shortening suggests
the ventricular dysfunction during AB 8 weeks stage. Functional
studies by echocardiography showed that treatment with Mdivi
ameliorates the left ventricular dysfunction in AB 8 weeks group
(Figure 1), which is further supported by other immunohisto-
chemical and molecular data.
Studies report that imbalance in capillary-myocyte ratio is the
prime cause of transition from compensated hypertrophy to heart
failure [35,36]. We and others showed that increasing the
angiogenesis during pressure overload hemodynamic stress
protects the heart from injury [27,37]. Also, endostatin was shown
to be an inducer of autophagy [38]. Here we report that treatment
with Mdivi, not only induces angiogenesis by increasing expression
of CD31 and VEGF but also decreases the expression of anti
angiogenic factors (Figure 2, 3 & 4). MMPs and TIMPs play an
important role in inducing ventricular remodeling during cardiac
hemodynamic overload. Studies have shown the pro angiogenic
role of MMP-2 and anti angiogenic role of MMP-9 and TIMP-3
during this pathogenesis [2,39,40,41,42]. Besides, TIMP-3 was
also shown to cause apoptosis [43]. By inhibiting the mitophagy,
Mdivi increases the expression of pro angiogenic MMP-2 and
decreases the expression of anti angiogenic MMP-9 and TIMP-3
in IHC data (Figure 5 & 6). Besides, mRNA expression of MMP-9
and TIMP-3 was significantly decreased in Mdivi treated groups
(Figure 6). This suggests that decrease in expression of MMP-9 and
TIMP-3 by Mdivi prevents collagen deposition as evidenced by
the Masson’s trichrome staining of heart sections (Figure 5, 6 & 7).
Collagen content (fibrotic area) was analyzed in relation to entire
myocardium excluding the pericardium and tips of papillary
regions.
Apoptosis is defined as programmed cell death, while autophagy
is eating of particular cellular organelles. Selective removal of
mitochondria by autophagy is defined as mitophagy [44].Changes
in mitochondrial morphology affects the cell susceptibility to
apoptotic cell death and thus may involve in disease process [45].
Here we show increase in apoptosis by Tunel assay and activated
caspace-3 staining during pressure overload induced failure stage
compared to that of sham. Increase in expression of autophagy/
Figure 10. IHC staining of heart sections with mitophagy markers LC3 and P62 in sham, 8 weeks post-AB (AB 8 wks) treated with
vehicle control and Mdivi. A) Expression of LC3 is seen as green fluorescence intensity and P62 as red fluorescence intensity (scale bar- 10 mm). B)
Data represents mean 6SE from n=6 per group; *p,0.05 was considered significant compared to sham and
#p,0.05 compared to vehicle treated
group.
doi:10.1371/journal.pone.0032388.g010
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sated heart failure stage. Treatment with mitochondrial division
inhibitor (Mdivi), inhibits abnormal mitophagy, thus significantly
decreased apoptosis and also normalized expression of LC3, P62
to that of sham (Figures 8, 9 & 10). Direct effects of Mdivi on
cardiomyocyte mitochondria were shown previously in myocardial
ischemia reperfusion study [26].
Conclusions
Our findings suggest that Drp-1 inhibitor, Mdivi-1 inhibits
mitochondrial fission and thereby plays a role in a) ameliorating
left ventricular dysfunction during heart failure, b) increases
expression of CD31 and VEGF, thus angiogenesis, c) decreases
expression of anti angiogenic factors and also minimizes collagen
deposition, d) inhibits abnormal autophagy/mitophagy and also
apoptosis.
Limitations
This study being the first time to study the therapeutic effect of
Mdivi in pressure overload induced heart failure, we have to
optimize the dose and duration of the drug. From the previous
literature in kidney reperfusion studies, it was reported that a dose
of 50 mg/kg body weight was effective therapeutically. Although
we couldn’t look at the direct effect of Mdivi due to technical
limitation, we showed the effect through mitophagy markers. Also
we didn’t measure the blood levels of the drug as we injected the
drug intra peritoneal route directly.
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